Quantify is the leading provider of Nordic RWE, but we are also increasingly being asked to coordinate RWE studies beyond the Nordic countries. Quantify recently initiated a European RWE collaboration with UCB to conduct studies in Sweden, Germany, and France, focusing on treatment patterns among patients with psoriatic arthritis and axial spondyloarthritis.
High-quality, fit-for-purpose RWE is essential for a successful product launch in our current regulatory and payer environments where RWE is no longer optional. Creating and synthesizing RWE from multiple EU countries helps companies to develop a compelling value story across markets and take advantage of the unique characteristics of each country’s data.
A robust evidence generation programme is important not only to the success of innovative pharmaceuticals, but also to ensure that patients receive the best possible treatment. Get in touch with the Quantify team to learn about the strengths and limitations of various EU datasets to ensure you have an optimal data strategy in place.